Filing Flows › Adaptive Biotechnologies (ADPT) › Q3 2026 › vs Q2 2026
Adaptive Biotechnologies (ADPT) Q3 2026 vs Q2 2026 (quarter over quarter)
Adaptive Biotechnologies's revenue rose $12.3M (+17%) from $71.6M in Q2 2026 to $83.9M in Q3 2026.
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 9.1% | -10.6% | +19.7 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $83.9M | $71.6M | $12.3M | +17% |
| Other income, net | $3.3M | −$24.2M | $27.4M | — |
| Costs & expenses | $87.2M | $111M | −$24.3M | -22% |
| Operating costs | $84.4M | $87.3M | −$3.0M | -3% |
| Net earnings | $2.8M | −$39.9M | $42.7M | — |
| Cost of revenue | $19.9M | $20.2M | −$232K | -1% |
| Research & development | $18.6M | $19.2M | −$515K | -3% |
| Sales & marketing | $26.9M | $26.4M | $482K | +2% |
| General & admin | $18.5M | $21.2M | −$2.7M | -13% |
| Other operating costs | $428K | $423K | $5K | +1% |
| Operating cash sources | $16.8M | −$25.1M | $41.9M | — |
| Depreciation & amortization | $3.6M | $3.7M | −$89K | -2% |
| Share-based compensation | $10.4M | $11.1M | −$733K | -7% |
| Working capital & other | $7.2M | −$18.7M | $25.9M | — |
| Operating cash flow | $9.6M | −$6.4M | $16.0M | — |
| Free cash flow (OCF − capex) | $7.7M | −$7.6M | $15.3M | — |
| Capital expenditures | $1.9M | $1.2M | $745K | +63% |
Questions
How much did Adaptive Biotechnologies's revenue grow quarter over quarter in Q3 2026?
Adaptive Biotechnologies's revenue rose $12.3M (+17%) from $71.6M in Q2 2026 to $83.9M in Q3 2026.